Bedrijfsoverzicht
Guardant Health, Inc. is a precision oncology enterprise that delivers comprehensive blood and tissue testing solutions alongside specialized data sets to support oncology practices across the United States and international markets. Operating within the healthcare sector specifically under the diagnostics and research industry, the company focuses on advanced liquid biopsy technologies such as the Guardant360 CDx test for tumor mutation profiling and the Guardant360 Liquid test which monitors over 740 genes to support clinical decision-making. The company currently commands a substantial market capitalization of $10.31 billion while generating annual revenue of $982.02 million and employing a workforce of 2,490 individuals. These valuation and revenue metrics indicate that Guardant Health holds a significant position in the precision medicine landscape, reflecting strong investor confidence in its technological platform despite the inherent capital intensity of developing and deploying complex diagnostic tools in a competitive global health environment.
Financiële gezondheid
The company reported trailing twelve-month revenue of $982.02 million, yet recorded a net income loss of $-416,276,992 and an EBITDA of $-396,561,984, highlighting a substantial gap between top-line generation and bottom-line profitability that points to a heavy cost structure associated with research, development, and market expansion. This negative net income relative to revenue suggests that operating expenses are currently outpacing gross profits, a common characteristic for biotechnology firms investing heavily in R&D to secure regulatory approvals and market share. Free cash flow stands at $-88,105,872, indicating that the company is burning cash to fund its operations and growth initiatives, which necessitates access to external capital markets or existing liquidity reserves to maintain financial flexibility. Gross margin is calculated at 64.5%, demonstrating the high value add of the company's diagnostic products, while operating margin sits at -42.9% and profit margin at -42.4%, revealing that overhead costs significantly erode gross profits before reaching the bottom line. On the balance sheet, the company holds $1.20 billion in cash against $1.71 billion in debt, and with a debt-to-equity ratio marked as N/A, the firm carries a leveraged position that relies on its cash reserves to service obligations and fund ongoing operations. The current ratio of 4.84 indicates a robust short-term liquidity position, suggesting the company possesses ample current assets to cover its immediate liabilities without immediate distress. Return on Equity is listed as N/A due to the negative equity position, while Return on Assets is -15.6%, reflecting that the asset base is currently generating negative returns, a metric that typically characterizes early-stage growth companies prioritizing expansion over immediate capital efficiency.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the lack of earnings, whereas the forward P/E is listed at -126.02, a negative figure that implies the market is pricing in future earnings recovery or significant structural changes rather than current profitability. The price-to-book ratio is -103.42, a negative multiple that indicates the market values the company at a substantial discount relative to its book value, often seen in firms with significant intangible assets or accumulated losses that are not fully reflected on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 10.50 and an EV/EBITDA of -27.28, suggesting that investors are valuing the enterprise based on revenue generation potential rather than current cash flows or earnings power. The stock trades within a defined range, with a 52-week high of $120.74 and a 52-week low of $36.36, meaning the current share price sits at a level that reflects recent market volatility and sentiment shifts regarding the company's long-term commercialization prospects. The beta value of 1.65 indicates that the stock exhibits high price volatility relative to the broader market, moving with greater intensity than the S&P 500, which underscores the speculative nature of investing in a company with negative earnings and high operating leverage.
Growth & Income
Revenue growth year-over-year is reported at 39.4%, while earnings growth is N/A, illustrating a scenario where top-line expansion is occurring at a rapid pace but profitability has not yet materialized to match that revenue trajectory. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and cash reserves are being reinvested directly into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment strategy is typical for precision oncology companies that must continuously innovate to maintain regulatory clearances and competitive advantages in a rapidly evolving therapeutic landscape. The overall growth and income profile is characterized by aggressive top-line expansion coupled with significant cash burn, suggesting that the company's value proposition relies entirely on the successful transition to sustained profitability in the coming years rather than current dividend yields or earnings stability.